GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stratec SE (OTCPK:SRBZF) » Definitions » Cyclically Adjusted PS Ratio

Stratec SE (Stratec SE) Cyclically Adjusted PS Ratio : 1.92 (As of Jun. 06, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Stratec SE Cyclically Adjusted PS Ratio?

As of today (2024-06-06), Stratec SE's current share price is $72.9551. Stratec SE's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $37.93. Stratec SE's Cyclically Adjusted PS Ratio for today is 1.92.

The historical rank and industry rank for Stratec SE's Cyclically Adjusted PS Ratio or its related term are showing as below:

SRBZF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.8   Med: 4.96   Max: 9.22
Current: 2.28

During the past years, Stratec SE's highest Cyclically Adjusted PS Ratio was 9.22. The lowest was 1.80. And the median was 4.96.

SRBZF's Cyclically Adjusted PS Ratio is ranked worse than
50.94% of 477 companies
in the Medical Devices & Instruments industry
Industry Median: 2.15 vs SRBZF: 2.28

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Stratec SE's adjusted revenue per share data for the three months ended in Mar. 2024 was $4.548. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $37.93 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Stratec SE Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Stratec SE's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stratec SE Cyclically Adjusted PS Ratio Chart

Stratec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.39 8.28 8.23 4.24 2.21

Stratec SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.16 3.15 2.16 2.21 1.92

Competitive Comparison of Stratec SE's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Stratec SE's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stratec SE's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stratec SE's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Stratec SE's Cyclically Adjusted PS Ratio falls into.



Stratec SE Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Stratec SE's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=72.9551/37.93
=1.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stratec SE's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Stratec SE's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.548/125.0381*125.0381
=4.548

Current CPI (Mar. 2024) = 125.0381.

Stratec SE Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 3.989 99.543 5.011
201409 3.942 99.823 4.938
201412 4.107 99.543 5.159
201503 3.150 99.717 3.950
201506 3.347 100.417 4.168
201509 3.506 100.417 4.366
201512 3.615 99.717 4.533
201603 2.914 100.017 3.643
201606 4.407 100.717 5.471
201609 4.538 101.017 5.617
201612 5.178 101.217 6.397
201703 4.438 101.417 5.472
201706 4.796 102.117 5.873
201709 4.973 102.717 6.054
201712 5.721 102.617 6.971
201803 4.067 102.917 4.941
201806 4.783 104.017 5.750
201809 4.430 104.718 5.290
201812 5.036 104.217 6.042
201903 4.377 104.217 5.251
201906 5.817 105.718 6.880
201909 4.543 106.018 5.358
201912 5.129 105.818 6.061
202003 5.173 105.718 6.118
202006 5.836 106.618 6.844
202009 5.785 105.818 6.836
202012 7.081 105.518 8.391
202103 7.040 107.518 8.187
202106 8.292 108.486 9.557
202109 6.724 109.435 7.683
202112 5.743 110.384 6.505
202203 6.817 113.968 7.479
202206 5.366 115.760 5.796
202209 5.735 118.818 6.035
202212 5.830 119.345 6.108
202303 5.318 122.402 5.433
202306 5.750 123.140 5.839
202309 5.502 124.195 5.539
202312 6.659 123.773 6.727
202403 4.548 125.038 4.548

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Stratec SE  (OTCPK:SRBZF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Stratec SE Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Stratec SE's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Stratec SE (Stratec SE) Business Description

Traded in Other Exchanges
Address
Gewerbestrasse 37, Birkenfeld, RP, DEU, 75217
Stratec SE designs and manufactures automated analyzer systems for laboratory data management and solutions for molecular diagnostic sample preparation and stabilization. Its business segments are Instrumentation, Diatron and Smart Consumables. Its Instrumentation segment is engaged in designing and manufacturing automated analyzer systems for clinical diagnostics and biotechnology customers. The Diatron segment comprises the business with systems, system components, consumables, and tests in the low throughput hematology and clinical chemistry segment. Its Smart Consumables segment is engaged in developing and selling scientific materials, such as nucleic acid purification. The company generates maximum revenue from the Instrumentation segment.

Stratec SE (Stratec SE) Headlines

From GuruFocus